ProCE Banner Activity

Improving Outcomes in HER2-Negative Early Breast Cancer With Individualized Targeted Approaches

Clinical Thought

Expert highlights of how recent FDA approvals are expanding individualized treatment options with improved outcomes for HER2-negative early breast cancer.

Released: June 21, 2023

Share

Faculty

Laura M. Spring

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC in partnership with Smart Patients.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

Smart Patients

ProCE Banner

Disclosure

Primary Author

Laura M. Spring, MD

Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Laura M. Spring, MD: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, G1 Therapeutics, Novartis, Puma; researcher (paid to institution): Genentech, Gilead, Lilly, Merck, Phillips.